MAP3K1 sirna

MAP3K1 siRNA (Human)

Cat. Num. AAA8215374

• Gene Names: MAP3K1; MEKK; MEKK1; SRXY6; MEKK 1; MAPKKK1
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: MAP3K1; MAP3K1 siRNA (Human); MAPKKK1; MEKK; MEKK1; Mitogen-activated protein kinase kinase kinase 1; MAPK/ERK kinase kinase 1; MEK kinase 1; MEKK 1; MAP3K1 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: MAP3K1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 1512

• Applicable Applications for MAP3K1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human MAP3K1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for MAP3K1 sirna

siRNA to inhibit MAP3K1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 153945765
• NCBI GeneID: 4214
• NCBI Accession #: NP_005912.1
• NCBI GenBank Nucleotide #: NM_005921.1
• UniProt Accession #: Q13233
• Molecular Weight: 164,470 Da
• NCBI Official Full Name: mitogen-activated protein kinase kinase kinase 1
• NCBI Official Synonym Full Names: mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase
• NCBI Official Symbol: MAP3K1
• NCBI Official Synonym Symbols: MEKK; MEKK1; SRXY6; MEKK 1; MAPKKK1
• NCBI Protein Information: mitogen-activated protein kinase kinase kinase 1
• UniProt Protein Name: Mitogen-activated protein kinase kinase kinase 1
• Protein Family: MAP3K12-binding inhibitory protein
• UniProt Gene Name: MAP3K1
• UniProt Synonym Gene Names: MAPKKK1; MEKK; MEKK1; MEK kinase 1; MEKK 1
• UniProt Entry Name: M3K1_HUMAN

NCBI Description

The protein encoded by this gene is a serine/threonine kinase and is part of some signal transduction cascades, including the ERK and JNK kinase pathways as well as the NF-kappa-B pathway. The encoded protein is activated by autophosphorylation and requires magnesium as a cofactor in phosphorylating other proteins. This protein has E3 ligase activity conferred by a plant homeodomain (PHD) in its N-terminus and phospho-kinase activity conferred by a kinase domain in its C-terminus. [provided by RefSeq, Mar 2012]

Uniprot Description

MEKK1: a protein kinase of the STE11 family. Phosphorylates and activates MKK4 and -7, which in turn activate JNK1, -2 and -3. Contains 1 RING-type zinc finger. The RING finger domain of MEKK1 exhibits E3 ubiquitin ligase activity toward c-Jun. c-Jun is downregulated in response to osmotic stress via ubiquitination-mediated degradation by the RING finger domain of MEKK1. Overexpressed/overactivated in multiple tumor types. The Mek1/2 inhibitor U0126 blocks export of influenza viral particles and has been suggested as an antiviral treatment. Single mutations at the same point of each gene also associated with cardiofaciocutaneous syndrome, (also linked with Braf and Kras mutations), displaying morphological, cardiac and mental defects. Inhibitors: U0126, CI-1040/PD184352, PD-0325901 (Phase I cancer), ARRY-142886 (Phase 1, cancer).

Protein type: Kinase, protein; Ubiquitin conjugating system; Ubiquitin ligase; Protein kinase, Ser/Thr (non-receptor); Protein kinase, STE; EC 2.7.11.25; Ligase; STE group; STE11 family

Chromosomal Location of Human Ortholog: 5q11.2

Cellular Component: cytosol

Molecular Function: protein binding; zinc ion binding; MAP kinase kinase kinase activity; JUN kinase kinase activity; protein kinase binding; ATP binding; protein kinase activity

Biological Process: activation of MAPKK activity; wound healing; apoptosis; regulation of cell migration; protein amino acid phosphorylation; activation of JNK activity; toll-like receptor 2 signaling pathway; toll-like receptor 10 signaling pathway; toll-like receptor 5 signaling pathway; MyD88-dependent toll-like receptor signaling pathway; apoptotic mitochondrial changes; positive regulation of actin filament polymerization; transforming growth factor beta receptor signaling pathway; toll-like receptor signaling pathway; innate immune response; toll-like receptor 9 signaling pathway; actin cytoskeleton organization and biogenesis; toll-like receptor 4 signaling pathway

Disease: 46,xy Sex Reversal 6